JERSEY CITY, N.J., Feb. 13, 2020 /PRNewswire/ –SCYNEXIS, Inc., Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced that it has completed patient enrollment in...
Patient #1: Enrolled in mTNBC Phase 1b/2 – Injected on 9/27/2019. CTC (circulating tumor cells) dropped to zero in two weeks on 10/11/2019. Total CTC and EMT (Epithelial Mesenchymal Transition in Tumor Metastasis) dropped to zero after about one month of...
BURLINGAME, Calif., Feb. 13, 2020 (GLOBE NEWSWIRE) — Corvus Pharmaceuticals, Inc. (CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies with biomarker patient enrichment...
First Study to Explore a Treat-to-Target Strategy in Crohn’s Disease using Endoscopy to Guide Dose Adjustment First Study to Evaluate Intestinal Ultrasound Monitoring in an Interventional Setting VIENNA–(BUSINESS WIRE)–The Janssen Pharmaceutical Companies...
WAKEFIELD, Mass., Feb. 13, 2020 (GLOBE NEWSWIRE) –Innovation Pharma (Formerly known as Cellceutix) (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, is pleased to announce that preliminary top-line data from its Phase 1 trial (NCT03234465)...
Email
Text